European Penny Stocks To Watch In October 2026

The European markets have recently faced challenges, with the pan-European STOXX Europe 600 Index experiencing a decline amid soaring oil prices and geopolitical tensions. Despite these headwinds, certain investment opportunities remain intriguing, particularly in the realm of penny stocks. While the term 'penny stocks' might seem outdated, it still captures the essence of investing in smaller or newer companies that can offer significant growth potential when underpinned by strong financials.

Let's explore several standout options from the results in the screener.

FIPP (ENXTPA:FIPP)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: FIPP S.A. operates in the real estate sector both in Paris and internationally, with a market capitalization of €17.30 million.

Operations: The company's revenue is derived from three main segments: Shops (€0.06 million), Housing (€0.06 million), and Intended for Sale (€0.69 million).

Market Cap: €17.3M

FIPP S.A., operating in the real estate sector, has a market capitalization of €17.30 million and is considered pre-revenue with earnings significantly impacted by a large one-off gain of €8.8 million. Despite becoming profitable this year, its revenue remains below US$1 million (€805K). The company is debt-free and has seen a reduction in liabilities over time; however, short-term liabilities far exceed short-term assets (€5.9M vs €26.3M). While its Price-To-Earnings ratio (4.1x) suggests good value compared to the French market, high volatility persists, making it riskier than many French stocks.

• Click to explore a detailed breakdown of our findings in FIPP's financial health report.
• Explore historical data to track FIPP's performance over time in our past results report.

Verimatrix (ENXTPA:VMX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Verimatrix SA offers security solutions to safeguard digital content, applications, and devices both in France and globally, with a market cap of €26.27 million.

Operations: The company's revenue is derived from its Software Strategic Activity segment, totaling $41.68 million.

Market Cap: €26.27M

Verimatrix SA, with a market cap of €26.27 million, is unprofitable but has confirmed guidance for a return to growth in Anti-Piracy revenue for 2026. Despite its high net debt to equity ratio of 52.5%, the company holds sufficient cash runway for over three years if it maintains current free cash flow levels. Its strategic partnership with Kaltura Inc. enhances its position in content protection, crucial given the demand for secure OTT and Cloud TV services. The management team and board are experienced, yet share price volatility remains high compared to most French stocks, indicating potential risk factors.

• Click here and access our complete financial health analysis report to understand the dynamics of Verimatrix.
• Explore Verimatrix's analyst forecasts in our growth report.

Nightingale Health Oyj (HLSE:HEALTH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nightingale Health Oyj is a health technology company that provides advanced health checks for detecting disease risks across various regions including Finland, Europe, the Middle East, Africa, the Americas, and Asia-Pacific with a market cap of €81.64 million.

Operations: The company's revenue is primarily generated from its Medical Labs & Research segment, amounting to €5.50 million.

Market Cap: €81.64M

Nightingale Health Oyj, with a market cap of €81.64 million, is unprofitable but debt-free and has ample short-term assets (€40.7M) covering liabilities. Its revenue from Medical Labs & Research reached €5.50 million, showing modest growth despite ongoing losses (€18.47M). Recent strategic partnerships expand its health check services across Europe and the Americas, including agreements with The Private GP Group and Michael J. Fox Foundation for proteomics analysis worth US$6.5 million. However, high share price volatility persists alongside an inexperienced management team (1.7 years average tenure), presenting potential risks for investors in this penny stock space.

• Navigate through the intricacies of Nightingale Health Oyj with our comprehensive balance sheet health report here.
• Learn about Nightingale Health Oyj's future growth trajectory here.

Next Steps

• Access the full spectrum of 299 European Penny Stocks by clicking on this link.
• Seeking Other Investments? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com